Latest News in the pharma Industry

Research & Development

Allergan completes AqueSys acquisition, adding XEN45 minimally invasive implantable shunt for glaucoma

Allergan completes AqueSys acquisition, adding XEN45 minimally invasive implantable shunt for glaucoma

19 Oct 2015

XEN45 approved in global markets and in in late-stage development in the US.

Read more 
Eleven Biotherapeutics completes enrolment in pivotal Phase III study of isunakinra (EBI-005) in patients with allergic conjunctivitis

Eleven Biotherapeutics completes enrolment in pivotal Phase III study of isunakinra (EBI-005) in patients with allergic conjunctivitis

16 Oct 2015

Eleven granted isunakinra as the international nonproprietary name for EBI-005.

Read more 
Lilly to discontinue development of evacetrapib for high-risk atherosclerotic cardiovascular disease

Lilly to discontinue development of evacetrapib for high-risk atherosclerotic cardiovascular disease

12 Oct 2015

Phase III trial terminated due to insufficient efficacy.

Read more 
Eli Lilly expands New York City R&D site

Eli Lilly expands New York City R&D site

9 Oct 2015

Expansion will power immuno-oncology discovery and research collaborations.

Read more 
Boehringer's investigational biologic cleared skin better, faster and for longer than ustekinumab in Phase II psoriasis study

Boehringer's investigational biologic cleared skin better, faster and for longer than ustekinumab in Phase II psoriasis study

9 Oct 2015

Nearly triple the percentage of patients maintained completely clear skin on BI 655066 after nine months, compared to ustekinumab.

Read more 
Concert Pharmaceuticals announces $8 million milestone from Celgene

Concert Pharmaceuticals announces $8 million milestone from Celgene

9 Oct 2015

Phase I clinical evaluation of CTP-730 completed.

Read more 
Horizon Discovery Group in-licenses oncology programme from Servier and enters option agreement

Horizon Discovery Group in-licenses oncology programme from Servier and enters option agreement

7 Oct 2015

Horizon will exploit its translational genomics and combination sciences platform to define optimum approaches to treatment and identify cancer patient populations most likely to respond.

Read more 
Bi-bi breast cancer — new in vitro treatment study begins in oxford

Bi-bi breast cancer — new in vitro treatment study begins in oxford

7 Oct 2015

Redesigned bi-specific antibodies may offer new hope against secondary breast cancer.

Read more 
Flex Pharma demonstrates efficacy of synthesized single and combination agents in reducing human muscle cramps

Flex Pharma demonstrates efficacy of synthesized single and combination agents in reducing human muscle cramps

7 Oct 2015

Presentation at the European Committee for Treatment and Research of Multiple Sclerosis

Read more 
NIH grantees win 2015 Nobel Prize in chemistry

NIH grantees win 2015 Nobel Prize in chemistry

7 Oct 2015

Prize awarded for mapping, at a molecular level, how cells repair damaged DNA and safeguard the genetic information.

Read more 
FDA grants Priority Review for Daklinza (daclatasvir) sNDAs

FDA grants Priority Review for Daklinza (daclatasvir) sNDAs

6 Oct 2015

Three applications are under review for Daklinza in combination with sofosbuvir with or without ribavirin to treat chronic hepatitis C patients with decompensated cirrhosis, post-liver transplant recurrence of HCV, and coinfection with HIV-1.

Read more 
FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

2 Oct 2015

Sandoz is seeking approval for all indications included in the reference product's label.

Read more